18 Results
Sort By:
Published on May 12, 2023
Research led by scientists from Cologne University, Amsterdam UMC and Copenhagen University has shown that a chemo free drug combination therapy can yield better results as well as fewer side effects for young people suffering from chronic lymphocytic leukemia (CLL). CLL is a cancer of the blood and bone marrow…
Published on January 30, 2020
Ibrutinib, a drug used to suppress chronic lymphocytic leukemia (CLL), acts through a genetic program shared by all patients. However, the program may be executed quickly, or slowly, depending on the patient. The speed with which the program is executed appears to correlate with molecular markers present in pretreatment patient…
Published on February 27, 2024
Researchers at the University of Pennsylvania report a variant of the p53 protein may improve the effectiveness of chimeric antigen receptor (CAR) T cell therapy. The findings are published in The Proceedings of the National Academy of Sciences and led by Carl June, MD, the Richard W. Vague Professor in…
Published on February 2, 2024
Researchers from Sylvester Comprehensive Cancer Center, Memorial Sloan Kettering, and other institutions report that a new BTK-targeting drug compound has shown promise to overcome treatment resistance of chronic lymphocytic leukemia (CLL). The results of the Phase I research, published today in the journal Science, show that the compound called NX-2127…
Published on January 19, 2024
In a crucial Phase I/II trial, researchers at The University of Texas MD Anderson Cancer Center have reported significant success in treating patients with relapsed or refractory B-cell malignancies using cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19. The findings, published in Nature Medicine, show…
Published on December 18, 2023
Sponsored content brought to you by Identifying tumor biomarkers and characterizing their function in cancer cells help provide valuable data to guide the development and selection of personalized therapies and treatment plans for patients that may improve health outcomes and survivorship. The pace of innovation in precision medicine testing technologies…
Published on December 13, 2023
A new study reveals insight into the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes (MDS). The findings, presented at the American Society of Hematology’s annual meeting, showed that treatment with drugs targeting two genetic mutations in MDS improved responses in mouse models. “We know that…
Published on June 29, 2023
Genomics pioneer Dennis Lo and Prenetics are collaborating to create a new company focused on early cancer detection. The firm, Insighta, will use the breakthrough FRAGMA technology Lo published on in 2022. Prenetics will provide $80M in cash and $20M in stock for the 50/50 joint venture, which, according to…
Published on February 10, 2023
Nathan Vardi Nathan Vardi, author of the new book For Blood and Money spent some time talking to IPM’s editor in chief Damian Doherty about this thrilling and dramatic true story of a small California biotech company and its quest to discover a blockbuster drug for…
Published on January 3, 2023
Amanda Paulovich, MD, PhDprofessor and Aven Foundation endowed chairFred Hutchinson Cancer Center Data drives many modern advances in understanding and treating cancer. In particular, proteogenomics—the combination of data from the genomes and proteomes—promises ways to better understand the pathways that underlie cancer and how to treat…
Published on March 17, 2022
Deepcell, a Silicon Valley life sciences company using artificial intelligence (AI) to identify and isolate single cells based on their morphology, has raised $73 million in Series B funding to continue to progress its unique platform. Koch Disruptive Technologies led the round, which brings the company’s overall funding to almost…
Published on August 21, 2020
A team of researchers at the German Cancer Research Center (DKFZ) and the Berlin Institute of Health (BIH) have released new data that highlights a potential new target for cancer immunotherapies. The scientists found that the metabolic enzyme IL4I1 (Interleukin-4-Induced-1) promoted the spread of tumor cells and suppressed the immune…
Published on March 25, 2020
Sponsored content brought to you by Chronic Lymphocytic Leukemia (CLL) is the most common form of blood cancer in adults, with an estimated incidence of up to 5.5 per 100,000 people worldwide. Alison Tang, a graduate student in the lab of Angela Brooks at the University of California, Santa Cruz,…
Published on January 21, 2020
Scientists at University College London (UCL) have found that testing for gene expression biomarkers in blood could predict the onset of active tuberculosis (TB) disease three to six months before symptoms develop. The researchers’ studies indicated that eight different transcript signatures, regulated by interferon signaling, demonstrated equal accuracy for diagnosing…
Published on June 28, 2019
Personalized diagnostics and therapeutics developer Adaptive Biotechnologies has raised at least $300 million in gross proceeds through an initial public offering (IPO)—the second-largest one for a biopharma company so far this year—then saw its share price double as investors flocked to the stock. Shares of Adaptive debuted for trading June…